News

Protein Potential’s R&D program is focused on vaccine development. The company has ongoing projects targeting vaccines for infectious diseases like malaria and bioterrorism agents including anthrax. Protein Potential’s

Perrigo is a global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. Analpram HC Cream

The nCounter miRNA expression assay kits enable researchers to perform multiplexed, direct digital detection and counting of miRNAs at single-base resolution, without the need for PCR amplification. NanoString’s

OSI Pharmaceuticals said that the new approval for Tarceva was based on data from the pivotal Phase III Saturn study. Saturn showed that Tarceva given as a maintenance

Reportedly the contract valued at circa GBP1.5m. Work on the project is expected to begin shortly and GMP manufacturing is expected to complete in early 2012. Gordon Sherriff,

Ceplene is approved in the EU for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission. The launch is being

Phase Forward management and employees are expected to join Oracle as part of the Oracle Health Sciences Global Business Unit. The combination is expected to enable researchers, clinical

APiX chromogenic technology allows for the detection of any biotinylated molecule, generating light grey-to-black spots that are visible to the naked eye and can be scanned with the

Aterovax said that the phospholipases A2 (PLA2) superfamily of enzymes plays a key role in the inflammatory process by generating chemical intermediates. The activity of secretory PLA2 (sPLA2)